BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression

Cell Death and Disease

Volumn 3, Issue 10, 2012, Pages

  Persano, L ^a   Pistollato, F ^a   Rampazzo, E ^a   Della Puppa, A ^a   Abbadi, S ^a   Frasson, C ^a   Volpin, F ^a   Indraccolo, S ^b   Scienza, R ^a   Basso, G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

BMP2; Glioblastoma; HIF 1 ; Hypoxia; MGMT; Temozolomide

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIZATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; DACARBAZINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; NEOPLASTIC STEM CELLS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84870481111     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.153     Document Type: Article

References (48)

1. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 2009; 64: 647-655.
2. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
3. Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010; 28: 851-862.
4. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007; 25: 1470-1475.
5. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26: 4189-4199.
6. Altaner C. Glioblastoma and stem cells. Neoplasma 2008; 55: 369-374.
7. Sanchez-Martin M. Brain tumour stem cells: implications for cancer therapy and regenerative medicine. Curr Stem Cell Res Ther 2008; 3: 197-207.
8. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008; 68: 5706-5715.
9. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 2009; 65: 866-875; discussion 875.
10. Della Puppa A, Persano L, Masi G, Rampazzo E, Sinigaglia A, Pistollato F et al. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? J Neurooncol 2011; 106: 33-41.
11. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012; 118: 4201-4211.
12. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
13. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7: 733-736.
14. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102: 789-795.
15. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-3284.
16. Pistollato F, Chen HL, Rood BR, Zhang HZ, D'Avella D, Denaro L et al. Hypoxia and HIF1alpha repress the differentiative effects of BMPs in high-grade glioma. Stem Cells 2009; 27: 7-17.
17. Pistollato F, Chen HL, Schwartz PH, Basso G, Panchision DM. Oxygen tension controls the expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes. Mol Cell Neurosci 2007; 35: 424-435.
18. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
19. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009; 9: 381-390.
20. Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 2010; 133(Pt 7): 1961-1972.
21. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444: 761-765.
22. Pistollato F, Rampazzo E, Abbadi S, Della Puppa A, Scienza R, D'Avella D et al. Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells. PLoS One 2009; 4: e6206.
23. Tate CM, Pallini R, Ricci-Vitiani L, Dowless M, Shiyanova T, D'Alessandris GQ et al. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ 2012; 19: 1644-1654.
24. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008; 13: 69-80.
25. Pistollato F, Persano L, Puppa AD, Rampazzo E, Basso G. Isolation and expansion of regionally defined human glioblastoma cells in vitro. Curr Protoc Stem Cell Biol 2011; Chapter 3: Unit 3.4.
26. Fedele AO, Whitelaw ML, Peet DJ. Regulation of gene expression by the hypoxia-inducible factors. Mol Interv 2002; 2: 229-243.
27. Liao SY, Lerman MI, Stanbridge EJ. Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development. BMC Dev Biol 2009; 9: 22.
28. Lopez-Rovira T, Chalaux E, Massague J, Rosa JL, Ventura F. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J Biol Chem 2002; 277: 3176-3185.
29. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010; 133(Pt 4): 983-995.
30. Trentin D, Hall H, Wechsler S, Hubbell JA. Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc Natl Acad Sci USA 2006; 103: 2506-2511.
31. Salacz ME, Watson KR, Schomas DA. Glioblastoma: Part I. Current state of affairs. Mol Med 2011; 108: 187-194.
32. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
33. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002; 99: 7021-7026.
34. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008; 6: 515-522.
35. Persano L, Rampazzo E, Della Puppa A, Pistollato F, Basso G. The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. ScientificWorldJournal 2011; 11: 1829-1841.
36. Reynolds CP, Sun BC, DeClerck YA, Moats RA. Assessing growth and response to therapy in murine tumor models. Methods Mol Med 2005; 111: 335-350.
37. Wakimoto H, Mohapatra G, Kanai R, Curry Jr WT, Yip S, Nitta M et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro-oncol 2012; 14: 132-144.
38. Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003; 9: 1033-1038.
39. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 2007; 13: 2441-2448.
40. Jensen RL, Ragel BT, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 2006; 78: 233-247.
41. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, Teraoka M et al. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 2007; 30: 793-802.
42. Zhou Z, Sun L, Wang Y, Wu Z, Geng J, Miu W et al. Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells. Cancer Biother Radiopharm 2011; 26: 77-83.
43. Stupp R, Hegi ME. Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol 2007; 25: 1459-1460.
44. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncol 2009; 11: 281-291.
45. Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 2006; 12: 4747-4754.
46. Barliya T, Mandel M, Livnat T, Weinberger D, Lavie G. Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy. PLoS One 2012; 6: e22849.
47. Huang H, Lin H, Zhang X, Li J. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. Oncol Rep 2012; 27: 2050-2056.
48. Razorenova OV, Ivanov AV, Budanov AV, Chumakov PM. Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene 2005; 350: 89-98.